Zacks Investment Research on MSN17h
CytomX Therapeutics (CTMX) Upgraded to Strong Buy: Here's What You Should Know
CytomX Therapeutics (CTMX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which ...
Zacks Investment Research on MSN17h
Veeva (VEEV) Upgraded to Strong Buy: Here's Why
Veeva Systems (VEEV) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one ...
5 “Strong Buy” European and Chinese Tech Stocks Outpacing the S&P 500 in 2025
Analysts are showing growing confidence in European and Chinese tech stocks as they outperform the S&P 500 (SPX). Many ...
24/7 Wall St.3d
Strong Buy dividend stocks
Quality dividend stocks yielding 7% and more are the best ideas for many investors now. These five are too cheap to ignore any longer. You can follow him investing $500,000 of his own money on our top ...
Nasdaq1mon
Durect (DRRX) Upgraded to Strong Buy: Here's Why
Durect (DRRX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates ...
Solid Biosciences (SLDB) Gets a Buy from Truist Financial
In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Solid Biosciences (SLDB – Research Report). The company’s ...